Verastem Inc. reported preliminary, unaudited net product revenues of approximately USD 17.5 million for the fourth quarter (Q4) of 2025 and approximately USD 30.9 million for the full year (FY) 2025, following U.S. FDA approval of AVMAPKI FAKZYNJA CO-PACK in May 2025. The company’s preliminary, unaudited cash, cash equivalents, and investments totaled USD 205 million as of December 31, 2025, with pro-forma year-end cash, cash equivalents, and investments of USD 234 million, inclusive of net proceeds from the exercise of expiring cash warrants. Verastem Inc. stated that its expected cash runway extends into the first half of 2027. Business highlights for the period include continued advancement of the clinical development program for VS-7375, a highly selective oral KRAS G12D (ON/OFF) inhibitor, targeting several advanced KRAS G12D solid tumor indications. The company plans to report an update on the safety and efficacy of the RAMP 205 expansion cohort with at least six months of follow-up on all patients in the second quarter (Q2) of 2026. Verastem Inc. leadership will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in February 2026. The company characterized 2025 as a transformative year in its business update.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-010036), on February 04, 2026, and is solely responsible for the information contained therein.